October 06, 2026 – PRESSADVANTAGE –
Material selection can influence far more than the physical form of a controlled-release dosage form. In polymeric drug delivery, the polymer system can affect how an active pharmaceutical ingredient is incorporated, how the product is processed, how the API is released, and what manufacturing conditions the formulation must tolerate as development progresses.
For development teams, polymer selection therefore has to be considered alongside the API, intended release profile, dosage-form geometry, processing method, and later manufacturing requirements. ProMed Pharma works with polymer-based controlled-release and long-acting dosage forms in which those variables interact, making material selection part of the formulation and process strategy rather than a stand-alone excipient decision.
Silicone, ethylene vinyl acetate, and poly(lactic-co-glycolic acid) illustrate how different polymer systems create different formulation and processing considerations. Silicone has a long history in drug delivery because of its chemical inertness, stable mechanical properties, and ability to incorporate APIs within the polymer matrix. ProMed Pharma identifies drug release in silicone systems as generally proportional to drug loading, with approximately 5% to 50% by weight cited as a typical range in this context. The appropriate loading remains formulation- and API-dependent.
EVA provides another route to controlled release. Changes in vinyl acetate content can influence release rate, giving formulation teams an additional material variable when developing a target profile. ProMed cites typical EVA processing temperatures of approximately 50 to 100 degrees Celsius. For APIs susceptible to thermal degradation, that processing range may affect whether the material remains practical as the formulation moves into process development.
Biodegradable polymers introduce a different release mechanism and set of tradeoffs. PLGA degrades through hydrolysis to lactic and glycolic acid while supporting controlled drug release. In biodegradable dosage forms and sustained-release microspheres, polymer characteristics can interact with particle properties, drug loading, and formulation conditions to influence release behavior. The material is therefore doing more than carrying the API; its behavior over time becomes part of how the dosage form functions.
Polymer choice also has to remain workable under the manufacturing process. ProMed Pharma’s work with drug-loaded polymer systems identifies API properties, API particle size, mixing or compounding method, cure or processing temperature, pressure, and dosage-form geometry as variables that can influence drug-content uniformity and release consistency. A formulation that looks promising during feasibility may still require additional process development as equipment, operating conditions, and scale become more representative of later manufacturing.
The relationship is especially clear when comparing molding and extrusion. Molding can support dosage forms requiring more complex geometries, while extrusion is often suited to scalable, efficient production of rod-like implants. Coextrusion and overmolding with drug-free polymer layers may also be used in certain systems to influence release behavior. These are more than shaping operations because geometry, layer structure, compounding, and process conditions can become part of the drug-product design.
Analytical development provides the evidence needed to determine whether a polymeric drug delivery system is producing the intended result. ProMed Pharma’s analytical work includes drug assay, impurities, content uniformity, real-time and accelerated in-vitro elution, and stability testing. During early development, R&D methods may be used to compare formulations and process conditions. As a program advances, methods, specifications, and stability work become more formal and phase-appropriate, without collapsing method development into validation or preliminary specifications into commercial requirements.
As development advances, an early material choice has to hold up under increasingly representative manufacturing conditions. Release data, stability results, content uniformity, and process performance can show whether the formulation and manufacturing approach remain compatible as the process is refined and scaled. If that relationship changes during scale-up, the effect may extend beyond manufacturing efficiency to characteristics of the drug product itself.
For ProMed Pharma, material selection is most useful when it accounts for both the intended release profile and the manufacturing conditions the formulation will encounter as development advances. That connection helps determine whether an early formulation can progress toward a controlled, repeatable manufacturing process.
About ProMed Pharma:
Established in 2006, ProMed Pharma is a specialized CDMO focused on polymer-based controlled-release and long-acting drug-delivery systems and drug-device combination products. The company works with established and early-stage pharmaceutical, biotechnology, and medical-device companies on formulation, development, and manufacturing programs for complex polymer-based dosage forms.
For more information, visit: https://promedpharmallc.com
###
For more information about ProMed Pharma, contact the company here:
ProMed Pharma
Jim Arps
Jim.Arps@ProMedPharmaLLC.com
Media gallery
